Our Plate is Full so We’re Making the Plate Bigger
“I’m excited about our new team. We have talented people with a wealth of skills, and everyone is committed to expanding SCTPN’s mission.”
LUNCH & LEARN Featuring Irene Okeke, PharmD, RPH
2022 LUNCH & LEARN Clinical Trials Presentations begins this month with a presentation by Irene Okeke, PharmD, RPh, Senior Science Medical Liaison for Sickle Cell Disease with forma Therapeutics. Irene Okeke is a Doctor of Pharmacy by training and graduated...
Change That Is Good
I have deep appreciation and love for the outgoing president and co-founder of SCTPN Donnette Carroll. She gracefully, and masterfully groomed an idealistic and energetic young adult into her partner in service.
Cryptocurrencies and Artificial Intelligence for Nonprofit Organizations
As Futurus president, Nathan Chappell, notes, “The nonprofit sector is always inherently behind the private sector in technologies.
A New Year’s Message from the President
2020 was a challenging year indeed; one where stumbling blocks were turned into stepping stones. One where our true character was brought to the fore, and our tenacity was put to the test. We have lost many family and friends, much pain was experienced, and hope...
Health Years: A Story by Marqus Valentine
Marqus left us many memories
Terms You Should Know
These medical terms are commonly used in association with Sickle Cell Disease. Knowing and understanding these terms will aid you in having an informed conversation with your physician or allied healthcare professional. These terms will also help adults living with...
Learning About Sickle Cell Disease
All advocates and advocacy organizations work daily with the intent to increase public awareness and education about sickle cell disease.
Fatty Liver Disease More Widespread Than You Realize
Diagnosis
Because it often has no symptoms, doctors can miss fatty liver disease. Typical lab tests may not catch it either.
FDA Grants Orphan Drug Statis New CTX001 Gene Therapy Trial by the CRISPR-Vertex Partnership
CTX001 is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from TDT or severe SCD in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells.